News and Trends 30 Aug 2022 Hemophilia drug from Sanofi and Sobi has license application accepted for priority review by FDA The Biologics License Application (BLA) for Efanesoctocog alfa, a drug to treat the rare and life-threatening blood disease, hemophilia A, has been accepted for priority review by the U.S. Food and Drug Administration (FDA). Efanesoctocog alfa (BIVV001) is being developed and commercialized as part of a collaboration between Sanofi and Sobi was given the target […] August 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 22 Nov 2018 First Drug for Rare Inflammation Syndrome Approved by FDA The FDA has approved the first drug for the treatment of a rare condition in which the body produces too many active immune cells, developed in a Swiss-Swedish partnership. The antibody drug, emapalumab, is approved to treat primary hemophagocytic lymphohistiocytosis. This condition is a rare, often fatal syndrome in which the immune system produces too […] November 22, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2018 Swedish Biotech Can Now Fast-Track its Metabolic Disorder Drug Sobi will enter the clinic after the Investigational New Drug application for its rare metabolic disorder candidate was accepted by the FDA. The Swedish Orphan Biovitrum (Sobi) will begin clinical trials for SOBI003, its candidate for the rare metabolic disorder, Sanfilippo syndrome type A. This was made possible as the FDA’s accepted the company’s Investigational New Drug […] January 23, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2016 Roche hits a Speed Bump on the way to a Hemophilia Cure The Swiss pharma is gearing up for a battle with Novo Nordisk in Hemophilia, but a safety setback might slow its progress. There is a ‘bloody’ battle in Europe that no one is talking about: who will claim the next Hemophilia blockbuster drug? Roche has established itself as a force to be reckoned with via […] November 4, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email